Search
Pelthos Therapeutics Ord Shs
PTHSAdd to Watchlist
23.690USD
+0.170+0.72%
Market hours 09/24, 09:31（ET）
82.44MMarket Cap
LossP/E TTM
Pelthos Therapeutics Ord Shs (PTHS) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts
Buy
1 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
53.143USD+128.67%
PTHS Analyst Recommendation Trends
In the current month, PTHS has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PTHS average Analyst price target in the last month is 53.143.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
1
1
1
6
6
6
6
6
5
5
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
7
7
6
6
5
PTHS Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, PTHS EPS is projected to reach -2.624 in FY2026Q3, following reported EPS of -6.616 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-4.13
-3.28
-3.05
-2.62
-2.48
Actual
-6.81
-3.09
-6.62
--
--
Surprise
-64.98%
+5.65%
-117.12%
--
--
FAQs
What is Pelthos Therapeutics Ord Shs's expected revenue for the next quarter?
Pelthos Therapeutics Ord Shs's expected revenue is 17.98M.
What is Pelthos Therapeutics Ord Shs's price target?
Analysts forecast that Pelthos Therapeutics Ord Shs's price target is USD 53.14, with the highest forecast at USD 64.00 and the lowest forecast at USD 45.00.
How have Pelthos Therapeutics Ord ShsPTHS's recent earnings per share performed?
The market expectation was USD -6.62, while Pelthos Therapeutics Ord ShsPTHS's earnings per share (EPS) for the previous quarter was USD -3.09. EPS for the next quarter is expected at USD -2.62.
What is the analyst rating for Pelthos Therapeutics Ord Shs?
Based on the ratings of Pelthos Therapeutics Ord Shs's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.